Volume 49, Issue 6 pp. 1171-1177

Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose

Lorne Holland

Lorne Holland

From the Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas; and the Department of Pathology and Molecular Medicine and the Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada

Search for more papers by this author
Theodore E. Warkentin

Theodore E. Warkentin

From the Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas; and the Department of Pathology and Molecular Medicine and the Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada

Search for more papers by this author
Majed Refaai

Majed Refaai

From the Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas; and the Department of Pathology and Molecular Medicine and the Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada

Search for more papers by this author
Mark A. Crowther

Mark A. Crowther

From the Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas; and the Department of Pathology and Molecular Medicine and the Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada

Search for more papers by this author
Marilyn A. Johnston

Marilyn A. Johnston

From the Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas; and the Department of Pathology and Molecular Medicine and the Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada

Search for more papers by this author
Ravindra Sarode

Ravindra Sarode

From the Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas; and the Department of Pathology and Molecular Medicine and the Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada

Search for more papers by this author
First published: 01 June 2009
Citations: 157
Ravindra Sarode, MD, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, CS3.114, Dallas, TX 75390-9073; e-mail: [email protected].

MAC holds a Career Investigator Award from the Heart and Stroke Foundation of Canada. Some of the research presented in this paper was supported by Heart and Stroke Foundation of Ontario Operating Grant T6157 (TEW). LH was the recipient of the American Society of Hematology Research Trainee Award for the year 2005.

Abstract

BACKGROUND: Plasma transfusion is standard therapy for urgent warfarin reversal in the United States. “Four-factor” prothrombin complex concentrate (PCC), available in Europe, has advantages over plasma therapy for warfarin reversal; however, only “three-factor” PCCs (containing relatively low Factor [F]VII) are available in the United States.

STUDY DESIGN AND METHODS: The efficacy of a three-factor PCC for urgent warfarin reversal was evaluated in 40 patients presenting with supratherapeutic international normalized ratio (ST-INR > 5.0) with bleeding (n = 29) or at high risk for bleeding (n = 11). In 13 patients, pre- and posttherapy vitamin K-dependent factors were assayed. Historical controls (n = 42) treated with plasma alone were used for rate of ST-INR correction comparison.

RESULTS: Treatment with plasma alone (mean, 3.6 units) lowered the INR to less than 3.0 in 63 percent of historical controls. Low-dose (25 U/kg) and high-dose (50 U/kg) PCC alone lowered INR to less than 3.0 in 50 and 43 percent of patients, respectively. Additional transfusion of a small amount of plasma (mean, 2.1 units) increased the rate of achieving an INR of less than 3.0 to 89 and 88 percent for low- and high-dose PCC therapy, respectively. FII, F IX, and FX increments were similar for PCC-treated patients with or without supplemental plasma; FVII was significantly higher in the PCC plus plasma group compared to the PCC-only group (p = 0.001).

CONCLUSION: Three-factor PCC does not satisfactorily lower ST-INR due to low FVII content. Infusion of a small amount of plasma increases the likelihood of satisfactory INR lowering.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.